Asset Details
Do you wish to reserve the book?
PA-296 Intermittent preventive treatment (IPT) of malaria in pregnancy with mefloquine may reduce nevirapine levels among HIV-infected women
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PA-296 Intermittent preventive treatment (IPT) of malaria in pregnancy with mefloquine may reduce nevirapine levels among HIV-infected women
Do you wish to request the book?
PA-296 Intermittent preventive treatment (IPT) of malaria in pregnancy with mefloquine may reduce nevirapine levels among HIV-infected women
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PA-296 Intermittent preventive treatment (IPT) of malaria in pregnancy with mefloquine may reduce nevirapine levels among HIV-infected women
2023
Overview
BackgroundSub-Saharan Africa is the region with the highest burden of malaria and HIV worldwide, being pregnant women the most vulnerable populations. Mefloquine (MQ) for intermittent preventive treatment (IPTp) of malaria in pregnancy has shown to significantly reduce malaria-related adverse maternal outcomes. However, while effective in HIV-uninfected pregnant women, results from an EDCTP-funded placebo-controlled trial assessing the safety and efficacy of IPTp-MQ among HIV-infected pregnant women showed that MQ recipients had a two-fold increased risk of HIV mother-to-child transmission (MTCT) compared to the control group. In this analysis we aimed to determine the antiretroviral (ARV) drug levels among a sub-sample of pregnant women participating in the aforementioned trial by treatment arm.MethodsARV drug levels were determined by UPLC/MS/MS methodology (LLQ 2.5ng/mL, for all drugs) in venous and cord blood samples of 249 pregnant women enrolled from 2010 to 2012 in Manhiça, Southern Mozambique. ResultsNo significant differences in the maternal and foetal levels of nevirapine (NVP), lamivudine (3TC) and zidovudine (AZT) were found across groups. However, maternal levels of NVP tended to be decreased in MQ recipients compared to the placebo one among the subset of women transmitting the HIV to their infants (344.64 [558.99] vs 926.4 [619.67], p=0.054).ConclusionOur findings suggest potential pharmacological interactions between MQ and NVP that warrant caution in the administration of antimalarial drugs to HIV-infected women on ARV treatment.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD
